Date: 2013-07-01
Type of information: Grant
Company: Imaxio (France) Jenner Institute (UK)
Investors: European Commission’s Seventh Framework Program (FP7) European Vaccine Initiative (EU) Preclin Biosystems (Switzerland)
Amount: € 5.5 million
Funding type: grant
Planned used: This grant will be used to support development and phase I clinical trial of an S. aureus vaccine.
Others: * On July 1, 2013, Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, have announced an European Union award of € 5.5 million to support the‘Bellerophon Project’ consortium to develop a vaccine against Staphylococcus aureus (S. aureus). The funding will be used to complete pre-clinical tests as well as a Phase I clinical trial in humans in 2016.
The pan-European Bellerophon Project is comprised of four European institutions involved in vaccine development, each contributing specialist expertise and technology. It includes Imaxio, a French biotech company focused in immunology, which has coordinated the grant application. Imaxio\'s pro-immunogenic technology, IMX313, has been evaluated as part of this application. The Jenner Institute at Oxford University, UK, an academic institution with key expertise on S. aureus antigens and viral vector delivery systems, will coordinate the overall project. The consortium also includes the European Vaccine Initiative, a non-for-profit organization based in Germany specialized in vaccine development programs and coordination of European institutions. The fourth member is Preclin Biosystems, a Swiss contract research organization that has a strong expertise in preclinical efficacy models for infectious diseases.
Therapeutic area: Infectious diseases
